EZH2 and prostate adenocarcinoma: As illustrated in Figure 8A, overexpressed EZH2 was associated with unfavorable OS of patients with adrenocortical carcinoma (ACC), kidney renal clear cell carcinoma (KIRC), LGG, LIHC, mesothelioma (MESO), pheochromocytoma and paraganglioma (PCPG), and PRAD.